- Home
- RARE vs ICL Comparison
RARE vs ICL Comparison
Compare RARE & ICL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- ICL
- Stock Information
- Founded
- RARE 2010
- ICL 1968
- Country
- RARE United States
- ICL Israel
- Employees
- RARE N/A
- ICL N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- ICL Agricultural Chemicals
- Sector
- RARE Health Care
- ICL Industrials
- Exchange
- RARE Nasdaq
- ICL Nasdaq
- Market Cap
- RARE 5.2B
- ICL 5.8B
- IPO Year
- RARE 2014
- ICL N/A
- Fundamental
- Price
- RARE $46.51
- ICL $4.57
- Analyst Decision
- RARE Strong Buy
- ICL Sell
- Analyst Count
- RARE 14
- ICL 1
- Target Price
- RARE $86.79
- ICL $4.00
- AVG Volume (30 Days)
- RARE 947.6K
- ICL 824.2K
- Earning Date
- RARE 11-05-2024
- ICL 11-11-2024
- Dividend Yield
- RARE N/A
- ICL 4.42%
- EPS Growth
- RARE N/A
- ICL N/A
- EPS
- RARE N/A
- ICL 0.31
- Revenue
- RARE $522,745,000.00
- ICL $6,930,000,000.00
- Revenue This Year
- RARE $27.29
- ICL N/A
- Revenue Next Year
- RARE $18.30
- ICL $4.82
- P/E Ratio
- RARE N/A
- ICL $14.13
- Revenue Growth
- RARE 27.44
- ICL N/A
- 52 Week Low
- RARE $37.02
- ICL $3.79
- 52 Week High
- RARE $60.37
- ICL $5.54
- Technical
- Relative Strength Index (RSI)
- RARE 36.73
- ICL 57.87
- Support Level
- RARE $43.04
- ICL $4.35
- Resistance Level
- RARE $46.98
- ICL $4.54
- Average True Range (ATR)
- RARE 2.11
- ICL 0.11
- MACD
- RARE -0.31
- ICL 0.02
- Stochastic Oscillator
- RARE 34.47
- ICL 74.42
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About ICL ICL Group Ltd.
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and growing solutions. These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North and South America, and the Rest of the world.